admin – Page 3546 – Get News Story

Carcinoid Tumor Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight

DelveInsight “Carcinoid Tumor Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Carcinoid Tumor Syndrome, historical and forecasted epidemiology as well as the Carcinoid Tumor Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Carcinoid Tumor Syndrome Market Share @ Carcinoid Tumor Syndrome Market Outlook

Key Takeaways from the Carcinoid Tumor Syndrome Market Report

The increase in Carcinoid Tumor Syndrome Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
As per DelveInsight analysis, the Carcinoid Tumor Syndrome Market is anticipated to witness growth at a considerable CAGR.
The leading Carcinoid Tumor Syndrome Companies such as Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others.
Promising Carcinoid Tumor Syndrome Pipeline Therapies such as Octreotide, Everolimus, Pasireotide (SOM230), Telotristat etiprate, Lanreotide, Isolated Perfusion, Fentanyl sublingual spray and others.

Stay ahead in the Carcinoid Tumor Syndrome Therapeutics Market with DelveInsight’s Strategic Report @ Carcinoid Tumor Syndrome Treatment Market Size

Carcinoid Tumor Syndrome Epidemiology Segmentation in the 7MM

The epidemiology section of Carcinoid Tumor Syndrome offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Carcinoid Tumor Syndrome Epidemiology trends @ Carcinoid Tumor Syndrome Prevalence

Carcinoid Tumor Syndrome Drugs Market

The Carcinoid Tumor Syndrome Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Carcinoid Tumor Syndrome signaling in Carcinoid Tumor Syndrome are likely to uncover new therapeutic targets and further expand treatment options for patients.

Carcinoid Tumor Syndrome Treatment Market Landscape

The Carcinoid Tumor Syndrome treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Carcinoid Tumor Syndrome has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Carcinoid Tumor Syndrome treatment guidelines, visit @ Carcinoid Tumor Syndrome Treatment Market Landscape

Carcinoid Tumor Syndrome Market Outlook

The report’s outlook on the Carcinoid Tumor Syndrome market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Carcinoid Tumor Syndrome therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Carcinoid Tumor Syndrome drug and late-stage pipeline therapy.

Carcinoid Tumor Syndrome Drugs Uptake

The drug chapter of the Carcinoid Tumor Syndrome report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Carcinoid Tumor Syndrome.

Major Carcinoid Tumor Syndrome Companies

Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others.

Learn more about the FDA-approved drugs for Carcinoid Tumor Syndrome @ Drugs for Carcinoid Tumor Syndrome Treatment

Scope of the Carcinoid Tumor Syndrome Market Report

• Coverage- 7MM

• Study Period- 2019-2032

• Carcinoid Tumor Syndrome Companies- Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others.

• Carcinoid Tumor Syndrome Pipeline Therapies- Octreotide, Everolimus, Pasireotide (SOM230), Telotristat etiprate, Lanreotide, Isolated Perfusion, Fentanyl sublingual spray and others

• Carcinoid Tumor Syndrome Market Dynamics: Carcinoid Tumor Syndrome Market Drivers and Barriers

• Carcinoid Tumor Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Carcinoid Tumor Syndrome Executive Summary

3. Carcinoid Tumor Syndrome Competitive Intelligence Analysis

4. Carcinoid Tumor Syndrome: Market Overview at a Glance

5. Carcinoid Tumor Syndrome: Disease Background and Overview

6. Patient Journey

7. Carcinoid Tumor Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Carcinoid Tumor Syndrome Unmet Needs

10. Key Endpoints of Carcinoid Tumor Syndrome Treatment

11. Carcinoid Tumor Syndrome Marketed Products

12. Carcinoid Tumor Syndrome Emerging Therapies

13. Carcinoid Tumor Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Carcinoid Tumor Syndrome Market Outlook

16. Access and Reimbursement Overview of Carcinoid Tumor Syndrome

17. KOL Views

18. Carcinoid Tumor Syndrome Market Drivers

19. Carcinoid Tumor Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Carcinoid Tumor Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight

Prostate Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of all prostate cancer types , historical and forecasted epidemiology as well as the prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Prostate Cancer Market Share @ Prostate Cancer Market Outlook

Key Takeaways from the Prostate Cancer Market Report

In April 2025, Clarity Pharmaceuticals Inc., announced a study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.
In April 2025, Aragon Pharmaceuticals announced a study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival based on conventional or prostate specific membrane antigen-positron emission tomography (PSMA-PET) imaging evaluated by blinded independent central review (BICR).
In 2023, the 7MM had approximately 7,279,500 prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2024-2034).
The five-year prevalent cases of prostate cancer in the US was ~1,093,300 in 2023.
Among the EU4 and the UK, Germany accounted for the highest number of metastatic CRPC cases while, Spain had the lowest cases, in 2023.
As per the estimates, in the US, majority of the cases were found to be localized/locally advanced cases (Stage I-III), comprising approximately 56% of total cases, while nearly 33% belonged to biochemical recurrence/ progressive cases, and ~11% belonged to metastatic cases.
Around 43% of all metastatic prostate cancer cases are attributed for mCRPC and rest 57% are attributed for mCSPC.
The leading Prostate Cancer Companies such as Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.
Promising Prostate Cancer Pipeline Therapies such as 177Lu-PSMA-I&T, 64Cu-PSMA I&T, Apalutamide, Abiraterone acetate, Prednisone, Glucocorticoid and others.

Stay ahead in the Prostate Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Prostate Cancer Market Outlook

Prostate Cancer Epidemiology Segmentation in the 7MM

Total Prevalent cases of Prostate cancer
5 years Prevalent cases of Prostate cancer
Age-specific cases of Prostate cancer
Total cases of Prostate cancer by clinical stages
Total Prevalent cases of mCSPC

Download the report to understand which factors are driving Prostate Cancer Epidemiology trends @ Prostate Cancer Prevalence

Prostate Cancer Marketed Drugs

NUBEQA (darolutamide): Bayer

NUBEQA (darolutamide) is an oral androgen receptor inhibitor. It is indicated for the treatment of adult patients with nmCRPC and mCSPC/mHSPC in combination with docetaxel. NUBEQA is administered 600 mg, (two 300 mg tablets) orally twice daily. In 2023, Bayer reported that its global revenue from NUBEQA amounted to around USD 941 million.

ERLEADA (apalutamide): Johnson & Johnson Innovative Medicine (Janssen)

ERLEADA is a next-generation oral androgen receptor inhibitor. It is indicated for the treatment of patients with mCSPC/mHSPC and nmCRPC. ERLEADA is administered 240 mg orally once daily. In 2023, Johnson & Johnson Innovative Medicine reported that its global revenue from ERLEADA amounted to USD 2,387 million.

XTANDI (enzalutamide): Astellas Pharma/Pfizer

XTANDI is an orally bioavailable, organic, non-steroidal small molecule targeting the AR with potential antineoplastic activity. It is indicated for the treatment of patients with CRPC, mCSPC/mHSPC, nmCRPC with biochemical recurrence at high risk for metastasis. XTANDI is administered 160 mg orally once daily. In 2023, Pfizer reported that its global revenue from XTANDI amounted to USD 1,191 million.

Prostate Cancer Emerging Drugs

Opevesostat (MK-5684; ODM-208): Merck and Orion

Opevesostat is an oral, non-steroidal, and selective inhibitor of CYP11A1 discovered and developed by Orion and is being investigated for the treatment of hormone-dependent cancers, such as prostate cancer. In July 2024, Merck and Orion announced a mutual exercise of options providing Merck global exclusive rights to opevesostat for the treatment of mCRPC. Merck and Orion initiated OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650), two pivotal Phase III clinical trials evaluating opevesostat in combination with hormone replacement therapy (HRT), for the treatment of certain patients with mCRPC. Final results from the OMAHA1 trial are expected in 2028 and OMAHA2a trial final results are anticipated in 2030. In addition to these, Merck has also presented updated CYPIDES Phase II results of opevesostat mCRPC at ESMO Congress 2024.

CAN-2409: Candel Therapeutics

CAN-2409, Candel’s most advanced viral immunotherapy candidate, is a replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. Moreover, according to the company’s corporate presentation, the company expects to announce topline data from this clinical trial by Q4 2024 for its ongoing placebo-controlled, randomized pivotal Phase III clinical trial of CAN-2409 in patients with low-to-intermediate-risk, localized, non-metastatic-prostate-cancer-and-Phase-II-trial-for-patients-undergoing active surveillance for localized prostate cancer. The drug CAN-2409 is presently undergoing evaluation in a Phase I clinical trial to assess its safety and tolerability in patients.

KPG-121: Kangpu Biopharmaceuticals

KPG-121 is a modulator of the Cereblon (CRBN) E3 ubiquitin ligase complex CRL4-CRBN targeting rapid ubiquitination and degradation of casein kinase 1A1 (CK1a) and transcription factors Aiolos (IKZF3) and Ikaros (IKZF1). KPG-121 promotes anti-proliferation and anti-angiogenesis activities and enhances immunomodulatory properties. A Phase I study to evaluate the safety, pharmacokinetics, and efficacy of KPG-121 when combined with enzalutamide, abiraterone, or apalutamide for the treatment of patients with mCRPC or nmCRPC was completed in the US. KPG-121 was well tolerated and demonstrated a favorable pharmacokinetic profile as well as promising efficacy.

To learn more about Prostate Cancer treatment guidelines, visit @ Prostate Cancer Treatment Market Landscape

Prostate Cancer Drugs Market

Currently, the market holds a diverse range of therapeutic alternatives for treatment, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, radioligand therapies, GnRH receptor antagonists, and others in different lines of treatment. Androgen receptor pathway inhibitors are a mainstay of treatment for patients with prostate cancer. There are currently four approved androgen receptor pathway inhibitors in the United States: three anti-androgens — apalutamide, enzalutamide, and darolutamide, as well as an androgen receptor pathway inhibitor, abiraterone acetate.

Prostate Cancer Market Outlook

Prostate cancer starts as localized prostate cancer when only found in the prostate and surgery or radiation can be used to treat it. Sometimes, hormone therapy might also be used. Increased sophistication of prostate imaging has allowed for the rapid emergence of focal therapies such as focal laser ablation, high-intensity focal ultrasound (HIFU), irreversible electroporation (IRE), photodynamic therapy (VTP), and focal cryotherapy. Radical prostatectomy can be open (ORP), laparoscopic (LRP), or robotic-assisted (RARP). ORP is the traditional method, whilst LRP and RARP are increasing in popularity.

Prostate Cancer Companies

Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.

Learn more about the FDA-approved drugs for Prostate Cancer @ Drugs for Prostate Cancer Treatment

Scope of the Prostate Cancer Market Report

Coverage- 7MM
Study Period- 2020-2034
Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.
Prostate Cancer Pipeline Therapies- 177Lu-PSMA-I&T, 64Cu-PSMA I&T, Apalutamide, Abiraterone acetate, Prednisone, Glucocorticoid and others.
Prostate Cancer Market Dynamics: Prostate Cancer Market Drivers and Barriers
Prostate Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of Prostate Cancer

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Prostate Cancer Market Overview at a Glance

7. Disease Background and Overview

8. Treatment and Management

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed drug

12. Emerging Drugs

13. Prostate Cancer: 7MM Analysis

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Non-Small Cell Lung Cancer Market Share @ Non-Small Cell Lung Cancer Market Outlook

Key Takeaways from the Non-Small Cell Lung Cancer Market Report

In April 2025, Merck Sharp & Dohme LLC announced a Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC).
In April 2025, Allist Pharmaceuticals Inc. conducted a phase 3 study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy.
In April 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC.
About 10–15% of all lung cancers are SCLC, and about 80–85% are Non-Small Cell Lung Cancer.
In the US, in 2024, there were approximately 204,800 new cases of NSCLC cancer (~115,500 in men and ~89,300 in women.
The three main histological subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the US, approximately 59% of all lung cancers are adenocarcinomas. About 25% of all lung cancers are squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 6% of all lung cancers.
Among the age-specific contribution, age =65 years are affected more by NSCLC than age
In 2024, the total incident cases of NTRK1/2/3 gene fusion NSCLC in the US was around 450.
In biomarker specific specific cases, most number of cases is from PD-L1 followed by KRAS, EGFR. On the other hand, NTRK accounted for least number of cases whereas, BRAF accounted for approximately 5% cases.
The two main subtypes of KRAS NSCLC are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the United States, ~4,900 comprised of KRAS G12C, and ~13,300 comprised of KRAS non-G12C in 2024.
The increase in Non-Small Cell Lung Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
As per DelveInsight analysis, the Non-Small Cell Lung Cancer Market is anticipated to witness growth at a considerable CAGR.
The leading Non-Small Cell Lung Cancer Companies such as Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others.
Promising Non-Small Cell Lung Cancer Pipeline Therapies such as Amivantamab, Lazertinib, Pemetrexed 500 mg, Cisplatin, Gemcitabine, Furmonertinib 80 mg, ILX651 and others.

Stay ahead in the Non-Small Cell Lung Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Non-Small Cell Lung Cancer Market Outlook

Non-Small Cell Lung Cancer Epidemiology Segmentation in the 7MM

The epidemiology section of Non-Small Cell Lung Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Total incident cases of NSCLC
Gender-specific cases of NSCLC
Age-specific cases of NSCLC
Total incident cases of NSCLC by histology
Total cases of NSCLC by stages
Total incident cases of NSCLC by genetic mutation/biomarkers
Line wise Treated Cases of Metastatic NSCLC

Download the report to understand which factors are driving Non-Small Cell Lung Cancer Epidemiology trends @ Non-Small Cell Lung Cancer Prevalence

Non-Small Cell Lung Cancer Marketed Drugs

KEYTRUDA (pembrolizumab): Merck

KEYTRUDA is a PD-1-blocking antibody. It is mainly used for advanced cancers that have spread to other body parts or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-L1. KEYTRUDA was first approved in October 2015 by the US FDA as a monotherapy for metastatic NSCLC. Later, the labels were expanded in 2016, 2017, 2018, and in 2023. In October 2023, the FDA approved KEYTRUDA platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent KEYTRUDA as post-surgical adjuvant treatment for resectable (tumors =4 cm or node positive) NSCLC. The drug has also received approvals in EU4 and the UK (August 2016) and Japan (December 2016), where the labels were expanded as well. Recently in September 2024, Merck announced that the MHLW has approved new indications for KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment. Earlier in March 2024, Merck announced that the EC has approved KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment

TECENTRIQ (atezolizumab): Genentech/Roche

TECENTRIQ is a PD-L1-blocking antibody. It is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin with a calculated molecular mass of 145 kDa. According to Roche’s recent product development portfolio published in October 2024, the company anticipates submitting a filing for TECENTRIQ in the periadjuvant treatment of NSCLC in 2025.

Non-Small Cell Lung Cancer Emerging Drugs

Telisotuzumab vedotin: AbbVie

Teliso-V is an investigational antibody–drug conjugate targeting c-Met, a receptor tyrosine kinase overexpressed in tumors, including Non-small Cell Lung Cancer. Teliso-V has the potential to become an important new treatment option in non-small cell lung cancer, with an anticipated approval in 2L+ NSCLC in 2024. In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the most advanced programs in AstraZeneca’s ADC scientific platform and one of the three leading ADCs in the oncology pipeline of Daiichi Sankyo. In January 2023, a Phase III clinical trial, combined with immune checkpoint inhibitors for the first-line treatment for Non-Small Cell Lung Cancer without actionable genomic alterations, PD-L1 <50% (trial name: TROPION-Lung07), was initiated. No TROP2-directed therapies are currently approved for treating Non-Small Cell Lung Cancer patients. AstraZeneca and Daiichi Sankyo are interrogating Dato-DXd in 1L non-driver mutation patients with TROPION-Lung08 (trying to knock off the Keynote-024 regimen) and with TROPION-Lung07 (trying to dethrone Keynote-189 regimen, the most important indication for Merck’s KEYRTUDA), as well as covering 2L and 3L patients with TROPION-Lung01.

To learn more about Non-Small Cell Lung Cancer treatment guidelines, visit @ Non-Small Cell Lung Cancer Treatment Market Landscape

Non-Small Cell Lung Cancer Market Outlook

As more targetable mutations are discovered, and new targeted drugs are developed, patients and oncologists will have an expanding array of treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure sufficient data supports the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy.

Non-Small Cell Lung Cancer Drugs Uptake

The existing NSCLC treatment is mainly dominated by targeted therapies for mutations such as EGFR-sensitizing mutations, EGFR exon 20 insertions, ALK fusions, ROS1 fusions, BRAFV600E mutation, MET exon 14 skipping mutations, RET fusions, and KRASG12C mutation. EGFR mutations and ALK rearrangements are well-known genetic abnormalities that drive the development of NSCLC. The use of TKIs as a treatment approach has shown better results in terms of patient outcomes when compared to chemotherapy. EGFR mutations are frequently observed, EGFR exon 19 deletions and EGFR exon 21 L858R mutations. The FDA has approved various TKIs to treat these mutations, with TAGRISSO considered the standard treatment. GILOTRIF is approved for patients with other EGFR sensitivity mutations like S768I, L861Q, and G719X.

Major Non-Small Cell Lung Cancer Companies

Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others.

Scope of the Non-Small Cell Lung Cancer Market Report

• Coverage- 7MM

• Study Period- 2020-2034

• Non-Small Cell Lung Cancer Companies- Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others

• Non-Small Cell Lung Cancer Pipeline Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, Cisplatin, Gemcitabine, Furmonertinib 80 mg, ILX651 and others.

• Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer Market Drivers and Barriers

• Non-Small Cell Lung Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Non-Small Cell Lung Cancer Executive Summary

3. Non-Small Cell Lung Cancer Competitive Intelligence Analysis

4. Non-Small Cell Lung Cancer: Market Overview at a Glance

5. Non-Small Cell Lung Cancer: Disease Background and Overview

6. Patient Journey

7. Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Small Cell Lung Cancer Unmet Needs

10. Key Endpoints of Non-Small Cell Lung Cancer Treatment

11. Non-Small Cell Lung Cancer Marketed Products

12. Non-Small Cell Lung Cancer Emerging Therapies

13. Non-Small Cell Lung Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Non-Small Cell Lung Cancer Market Outlook

16. Access and Reimbursement Overview of Non-Small Cell Lung Cancer

17. KOL Views

18. Non-Small Cell Lung Cancer Market Drivers

19. Non-Small Cell Lung Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Musculoskeletal Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “Musculoskeletal Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of musculoskeletal pain epidemiology, market, and clinical development in musculoskeletal pain. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the musculoskeletal pain market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Musculoskeletal Pain Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Musculoskeletal Pain Market Size

Key Takeaways from the Musculoskeletal Pain Market Report

In January 2025:- Xalud Therapeutics Inc. announced aPhase 2a safety and efficacy study of XT-150 in adult participants experiencing back pain due to inflammation of the facet joint, also known as facet joint osteoarthritis (FJOA), and who are eligible for intra articular glucocorticoid injection, or radiofrequency ablation of medial branches of the primary dorsal ramus of the exiting nerve root, which innervates the adjacent facet joints.
The total 7MM prevalent cases of musculoskeletal pain in 2023 were around 147 million out of which the highest cases were seen in the United States.
EU4 and the UK accounted for 56 million cases in 2023. Among EU4 and the UK, France had the highest prevalent cases in 2023, followed by the United Kingdom. Conversely, Germany reported the lowest number of prevalent cases that year.
Assessments as per DelveInsight’s analysts showed that the highest number of musculoskeletal pain cases were reported in the 45–64 years age group, followed by the 18-44 years age group.
In 2023, there were approximately 36 million prevalent cases of musculoskeletal pain among males and approximately 41 million prevalent cases among females in the United States.
The leading Musculoskeletal Pain Companies such as Eli Lilly and Company, Sun Pharma Global FZE, Flexion Therapeutics, Taisho Pharmaceutical, Anika Therapeutics, Mesoblast, Regeneron Pharmaceutical, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Sorrento Therapeutics, Taiwan Liposome Company, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Techfields Pharma, Virios Therapeutics, Camurus, Braeburn Pharmaceuticals, Kolon TissueGene, Amzell, Seikagaku Corporation, Propella Therapeutics, Novartis Pharmaceuticals, Moebius Medical, Antibe Therapeutics, Aesculap Biologics, VivaTech, Xalud Therapeutics, Tonix Pharmaceuticals, ACADIA Pharmaceuticals, AstraZeneca, Charleston Laboratories and others.
Promising Musculoskeletal Pain Therapies such as EB-001, Lumiracoxib, Cyclobenzaprine, Diclofenac and Paracetamol, MEDI7352, and others.

Stay ahead in the competitive landscape of the Musculoskeletal Pain Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Musculoskeletal Pain Treatment Market Size

Musculoskeletal Pain Epidemiology Segmentation in the 7MM

Total Musculoskeletal Pain Diagnosed prevalent cases
Musculoskeletal Pain Age-specific cases
Musculoskeletal Pain Gender-specific cases

Download the report to understand which factors are driving Musculoskeletal Pain epidemiology trends @ Musculoskeletal Pain Prevalence

Musculoskeletal Pain Marketed Drugs

ZILRETTA: Flexion Therapeutics

ZILRETTA/ FX006 (triamcinolone acetonide) is an extended-release corticosteroid approved to manage osteoarthritis knee pain. It is the first and only extended-release, intra-articular therapy for patients confronting osteoarthritis knee pain. It employs proprietary microsphere technology combining triamcinolone acetonide, a commonly administered, immediate-release corticosteroid, with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. ZILRETTA received approval from the US FDA in October 2017. The pivotal Phase III trial, on which the approval of ZILRETTA was based, showed that the drug significantly reduced osteoarthritis knee pain for 12 weeks, with some people experiencing pain relief through Week 16.

LOQOA Tape: Taisho Pharmaceutical

Loqoa Tape (S-flurbiprofen, mentha oil) is a transdermal anti-inflammatory analgesic patch formulation indicated to treat osteoarthritis pain and inflammation. LOQOA Tape was co-developed by Taisho Pharmaceutical and Taisho Pharmaceutical Holdings’ consolidated subsidiary TOKUHON. It is marketed in Japan by Taisho Toyama Pharmaceutical and Teijin Pharma. In September 2015, LOQOA Tape was approved to treat osteoarthritis pain and inflammation in Japan. In Phase III clinical trials in which a flurbiprofen gel patch was administered as a controlled drug to patients with osteoarthritis of the knee joint, LOQOA Tape as a patch formulation to be applied once a day was found to significantly improve the pain in the patient’s knee joints. Regarding the safety profile, a 52-week long-term drug administration study confirmed that LOQOA Tape possesses good tolerability for patients with osteoarthritis.

Musculoskeletal Pain Emerging Drugs

Rexlemestrocel-L (MPC-06-ID): Mesoblast

Rexlemestrocel-L/MPC-06-ID is a candidate for treating chronic low back pain (CLBP) caused by disc degeneration. It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions. Mesoblast completed the Phase III trial of rexlemestrocel-L for CLBP. The study evaluated the efficacy and safety of a single injection of rexlemestrocel-L alone or combined with Hyaluronic Acid (HA) in subjects with chronic low back pain. It was seen that a single injection of rexlemestrocel-L + HA carrier resulted in at least 2 years of pain reduction with opioid-sparing activity in patients with CLBP due to degenerative disc disease.

TLC599: Taiwan Liposome Company

TLC599 is Taiwan Liposome’s proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) designed to provide sustained pain management for up to 24 weeks. TLC599 has the potential to enable patients to receive both immediate and sustained benefits from the local delivery of a highly potent and clinically validated steroid that typically has a very short half-life. It is the world’s first multilamellar and multivesicular lipid formulation of DSP for osteoarthritis and provides fast onset and sustained release of up to 6 months. TLC599 could achieve usage in 26% of all US knee OA patients. It is presently being studied in Phase III to treat osteoarthritis.

Discover the future of Musculoskeletal Pain Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Musculoskeletal Pain Market Drivers and Barriers

Musculoskeletal Pain Therapeutics Market

Musculoskeletal pain is often managed with a variety of drug classes, depending on the severity and underlying cause of the pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce inflammation and alleviate pain. For more severe pain, opioids like tramadol or oxycodone may be prescribed, although these are used cautiously due to their potential for addiction. Muscle relaxants, such as cyclobenzaprine, are also employed to ease muscle spasms. One of the most common classes is cyclooxygenase (COX) inhibitors, found in NSAIDs such as ibuprofen, naproxen, and celecoxib.

Musculoskeletal Pain Market Outlook

The market outlook for musculoskeletal pain management is promising, with significant advancements in both marketed and emerging therapies. ZILRETTA, from Flexion Therapeutics, remains a key player, offering extended-release pain relief for osteoarthritis knee pain through innovative microsphere technology. Similarly, Taisho Pharmaceutical’s LOQOA Tape, a transdermal patch for osteoarthritis pain, has shown strong safety and efficacy in long-term studies. Emerging therapies like Mesoblast’s Rexlemestrocel-L and Taiwan Liposome’s TLC599, which offer sustained pain relief for chronic low back pain and osteoarthritis, respectively, further highlight the potential for improved patient outcomes and market expansion in pain management.

Explore the dynamics of the Musculoskeletal Pain Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Musculoskeletal Pain Ongoing Clinical Trials Analysis

Scope of the Musculoskeletal Pain Market Report

Coverage- 7MM
Study Period- 2020-2034
Musculoskeletal Pain Companies- Eli Lilly and Company, Sun Pharma Global FZE, Flexion Therapeutics, Taisho Pharmaceutical, Anika Therapeutics, Mesoblast, Regeneron Pharmaceutical, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Sorrento Therapeutics, Taiwan Liposome Company, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Techfields Pharma, Virios Therapeutics, Camurus, Braeburn Pharmaceuticals, Kolon TissueGene, Amzell, Seikagaku Corporation, Propella Therapeutics, Novartis Pharmaceuticals, Moebius Medical, Antibe Therapeutics, Aesculap Biologics, VivaTech, Xalud Therapeutics, Tonix Pharmaceuticals, ACADIA Pharmaceuticals, AstraZeneca, Charleston Laboratories and others.
Musculoskeletal Pain Therapies- EB-001, Lumiracoxib, Cyclobenzaprine, Diclofenac and Paracetamol, MEDI7352, and others.
Musculoskeletal Pain Therapeutic Assessment: Musculoskeletal Pain Current Marketed and Musculoskeletal Pain Emerging Therapies
Musculoskeletal Pain Market Dynamics: Musculoskeletal Pain market drivers and Musculoskeletal Pain market barriers
Musculoskeletal Pain Unmet Needs, KOL’s views, Analyst’s views, Musculoskeletal Pain Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Musculoskeletal Pain Market Overview at a Glance

4 Executive Summary of Musculoskeletal Pain

5 Key Events

6 Epidemiology and Market Forecast Methodology

7 Disease Background and Overview

8 Treatment of Musculoskeletal Pain

9 Epidemiology and Patient Population

10 Musculoskeletal Pain Patient Journey

11 Musculoskeletal Pain Marketed Drugs

12 Musculoskeletal Pain Emerging Drugs

13 Musculoskeletal Pain: 7 Major Market Analysis

14 KOL Views

15 SWOT Analysis

16 Musculoskeletal Pain Unmet Needs

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Musculoskeletal Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Chronic Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “Chronic Pain Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock key insights into the Chronic Pain Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chronic Pain Market Size

Key Takeaways from the Chronic Pain Market Report

The total 7MM Chronic Pain Prevalent Cases in 2023 US accounted the highest cases.
Among the EU4 and the UK, the highest number of Chronic Pain prevalent cases were observed in the UK ~ 30%.
Prevalence of chronic pain increased with age and was higher among those in age group between 45-64 years.
Approximately 70% of chronic pain cases in the United States in 2023 fall within the category of moderate to severe severity-specific cases.
The Chronic Pain Companies such as AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
Promising Chronic Pain Therapies such as Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and others.

Stay ahead in the competitive landscape of the Chronic Pain Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Chronic Pain Treatment Market Size

Chronic Pain Epidemiology Segmentation in the 7MM

Total Chronic Pain Prevalent Cases
Total Chronic Pain Diagnosed Cases
Chronic Pain Severity-specific Cases
Chronic Pain Age-specific Cases
Chronic Pain Cause-specific Cases

Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Prevalence

Chronic Pain Marketed Drugs

JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International

JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku’s proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Improvement of symptoms of osteoarthritis (knee joint and hip joint) is expected by administering JOYCLU into the joint cavity once every 4 weeks. JOYCLU is the first joint function improvement agent in Japan to treat osteoarthritis of the hip joint.

ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an intra-articular injection to manage osteoarthritis pain in the knee. ZILRETTA is Flexion’s novel, proprietary, sustained-release formulation composed of triamcinolone acetonide (TA) embedded in a biodegradable PLGA matrix that extends residence time in the joint for the treatment of mild-to-moderate OA of the knee. ZILRETTA received approval from the FDA on October 2017.

Chronic Pain Emerging Drugs

ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals.

Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucuronoxylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). GAGs are complex carbohydrates that play a regulatory role in the body through interacting with proteins involved with inflammation. Key features of PPS activity are its anti-inflammatory and tissue regenerative properties, as well as its mild anti-thrombotic activity.

TNX-102 SL: Tonix Pharmaceuticals

TNX-102 SL, a sublingual tablet with 2.8 mg of cyclobenzaprine HCl, is taken nightly to treat fibromyalgia. Its rapid absorption and reduced production of a long-lasting active metabolite enhance its effectiveness. This patented formulation optimizes cyclobenzaprine delivery to improve sleep quality and minimize residual effects. TNX-102 SL, a centrally-acting analgesic, eases pain by enhancing sleep. It’s currently in mid-Phase III development for fibromyalgia management.

Discover the future of Chronic Pain Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Chronic Pain Market Drivers and Barriers

Chronic Pain Drugs Market

Currently, several types of medications are being used in the management of chronic pain, including acetaminophen, ibuprofen, aspirin, COX-2 inhibitors, antimigraine medications, sedatives, opioids, and antidepressants. Nonpharmacologic treatments for chronic pain can include exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, hypnosis, chiropractic medicine, and other treatments. There are several approved drugs for the treatment of chronic pain such as EMGALITY (galcanezumab-gnlm), AIMOVIG (erenumab), and AJOVY (fremanezumab), among others.

Chronic Pain Market Outlook

Key Chronic Pain Companies such as Paradigm Biopharmaceuticals, Centrexion Therapeutics, Tonix Pharmaceuticals, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Chronic Pain. According to DelveInsight’s analysis, the Chronic Pain Market Growth is expected to be mainly driven by increasing Chronic Pain Prevalence, rise in awareness and access to treatment, alternative options (such as a novel therapeutic agent) to addictive opioids, holistic approach, efforts by the organization and upsurge in the geriatric population.

Explore the dynamics of the Chronic Pain Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Chronic Pain Ongoing Clinical Trials Analysis

Scope of the Chronic Pain Market Report

Coverage- 7MM
Study Period- 2020-2034
Chronic Pain Companies- AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
Chronic Pain Therapies- Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and others.
Chronic Pain Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Chronic Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Chronic Pain Market Overview at a Glance

4 Executive Summary of Chronic Pain

5 Key events

6 Disease Background and Overview

7 Epidemiology and Patient Population

8 Patient Journey

9 Marketed Products

10 Emerging Therapies

11 Chronic Pain: The Seven Major Markets Analysis

12 SWOT Analysis

13 Unmet Needs

14 KOL Views

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

London-based Ethical Gig Platform for Home Services iDeliverr is Rewriting the Rules of the Handyman Economy

In an era where traditional gig platforms dominate but face growing criticism over worker pay and hidden fees, London-based startup iDeliverr is taking a radical stand. Founded by Kenneth Stuart, the platform promises to slash commissions by 50%, ensuring tradespeople earn more. At the same time, customers save – a move that could redefine the future of work in the UK’s £4 billion home services sector.

Traditional handyman platforms charge gig workers 15-30% per job, plus customer fees. For a £150 plumbing job, a worker nets just £105-£127.50 after fees. Customers pay 10-20% surcharges, inflating average costs by £18-£45. Today, 68% of London gig workers earn below the £13.15/hour living wage, which clearly demonstrates worker exploitation. There is no sick pay, pensions, or injury coverage for 92% of platform-based tradespeople. No wonder 41% of Londoners report “bait-and-switch pricing” on major platforms. 57% even struggle to verify worker qualifications pre-hiring. There is also an environmental impact, as 28% of gig jobs require cross-London travel, contributing to 12,000+ tonnes of CO2 annually.

To solve these issues, iDeliverr offers a fairer model. Here’s how iDeliverr addresses issues with traditional handyman platforms:

For Workers:

12% Commission: Half the industry average, letting a £150 job net workers £132 vs. £105-£127.50 elsewhere.
Dynamic Pricing: Urgent jobs pay 15-25% more; off-peak discounts incentivize scheduling.
Benefits Fund: 2% of platform fees go toward:
Accident insurance
Skills training (NVQ certifications)
Mental health support via Mind.org partnership.

For Customers:

1. No Hidden Fees: Price shown = price paid.

2. Money-Back Guarantee: 48-hour dispute resolution.

3. Tiered Verification:

Basic: DBS check, 2 references
Pro: NVQ certification, 5-year work history
Elite: Master Craftsman Guild members

Comparative Pricing Example Against a Traditional Handyman Platform

Kitchen Shelf Installation:

Traditional Handymen Platform: £189
iDeliverr: £149
Savings: £40 (21%)

Emergency Plumbing (2hrs):

Traditional Handymen Platform: £245
iDeliverr: £199
Savings: £46 (19%)

Full Home Paint Job:

Traditional Handymen Platform: £1,850
iDeliverr: : £1,550
Savings: £300 (16%)

Technology Deep Dive: The Coming App

AI-Powered Matching

Skill Graph Algorithm: Matches workers to jobs using 53 data points (e.g., tool availability, past ratings for similar tasks).
Travel Optimization: Reduces average commute by 22% vs. competitors (beta test data).

Security Features

End-to-end encryption for all chats/payments.
Facial recognition for worker profile verification.

Accessibility

Voice-to-text job posting for visually impaired users.
Multilingual support (12 languages at launch).

iDeliverr App:

Real-time earnings tracker for workers.
Augmented Reality tool for customers to visualize projects.

Case Studies: Beta Test Results

Case Study 1: Maria, Single Mother & Electrician

TaskRabbit Earnings (2023): £32,500/year (pre-tax, pre-fees).

iDeliverr Beta (2024): £41,200/year projected (22% fee reduction + surge pricing).

Case Study 2: The Patel Family Kitchen Reno

TaskRabbit Quote: £4,200 (excluding materials).

iDeliverr Cost: £3,550 via “Off-Peak Discount” booking.

Industry Reactions & Collaborations

Collaborators

Federation of Master Builders: “iDeliverr aligns with our ethics charter.” – Brian Berry, CEO.
British Safety Council: Collaboration on worker training modules.

An Excerpt from the Interview with the Founder Kenneth Stuart:

Q: Why tackle this industry?

Kenneth Stuart: My father was a carpenter – I saw how platforms eroded his pay despite 30 years’ experience.

Q: How will you sustain lower fees?

Kenneth Stuart: We automate 80% of admin costs via AI, unlike legacy players.

Milestones Achieved and Future Roadmap:

2024: London launch, 5,000-tasker goal.
2025: Expand to Birmingham, Manchester; B2B contracts.
2026: EU rollout; smart home integration.

To get involved, visit the local handyman near me.

Workers can join the waitlist at Handyman London

Investors can email support@ideliverr.co.uk

Media Contact
Company Name: iDeliverr
Contact Person: Kenneth Stuart, Founder
Email: Send Email
Phone: 020 8058 2771
City: London
Country: United Kingdom
Website: www.ideliverr.co.uk

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: London-based Ethical Gig Platform for Home Services iDeliverr is Rewriting the Rules of the Handyman Economy

ZHIYUN Shines Brighter at NAB 2025 With Latest Product Updates

Key influencers enthusiastic about new ZHIYUN lights and gimbals

Shenzhen, China – April 15th, 2025 – ZHIYUN was a hit at the NAB 2025 show in Las Vegas this April, unveiling new accessories that help photographers and videomakers unleash their creativity. The packed venue saw the launch of the latest ZHIYUN products and emphasized the remarkable performance of the wide range of ZHIYUN gimbal and lighting accessories.

The company drew a big crowd at its booth, with top influencers interacting with the audience, and live demonstrations for visitors and media. Industry experts speaking enthusiastically at the ZHIYUN booth included Cam Mackey @cammacky, Zach Ramelan @zachramelan, Irene Rudnyk @irenerudnykphoto, The DP Journey @thedpjourney, and Anita Sadowska @sadowskaphoto

The popular photo and video accessory maker held major new product launch events at its booth and also showcased key creative accessories from its range of popular ZHIYUN Molus, Fiveray and Cinepeer lights; and the Crane, Weebill and Smooth series gimbals. Organized by the US National Association of Broadcasters, NAB 2025 took place from April 6 to April 9, 2025 at the Las Vegas Convention Center in Las Vegas, Nevada, US.

ZHIYUN lights up brightly in Las Vegas

As well as exclusive new products, ZHIYUN showed visitors many of its outstanding range of lights and gimbals which are already in the field, helping photo and video creatives and professionals produce spectacular results quickly and easily.

There was the MOLUS G300, which Youtuber RudyVisuals highlights for its ability to act as a single versatile lighting source that illuminates an entire interview setup [https://www.youtube.com/watch?v=iALONIslQzo]. The similarly-capably G200 was also on show at NAB 2025.

The MOLUS X60 videography and photography light provides professional-level powerful 60 watt quality lighting, but is remarkably compact – palm-sized and just 319g – easy-to-use, and cool-running. Color fidelity is excellent, and the MOLUS X60 RGB variant provides full color control. Influencer, Connor McCaskill, after trying out this X60 series and the M20C light, excitedly comments about “how insanely powerful they are for how portable they are”. [https://www.youtube.com/watch?v=Yvqv99H6QVM]

ZHIYUN’s ultra-portable lights make working on the move even easier. The FIVERAY M40 light provides 40W of high power lighting in a lightweight palm-sized device that fits in a pocket. Meanwhile, the FIVERAY M20 and M20C pocket-sized 20W lights combine professional-level features with consumer-level ease-of-use in an easily portable format.

Then there’s ZHIYUN’s CINEPEER C100, a 100W RGB portable light with 36,000 color options, built-in lighting effects, adaptive charging, and long battery life.

Innovations in gimbals and AI tracking

The Crane M3S compact portable gimbal is a 705g (1.5 lbs) stabilizer with an impressive load-bearing capacity that handles a wide range of mainstream full-frame cameras and lens combos. It can also be used with mobile phones, mirrorless cameras, and action cameras.

Powerful AI tracking technology transforms the video creation process in ZHIYUN’s SMOOTH 5S AI smartphone stabilizer gimbals. Video experts are saying it is “going to change your way of smartphone filming a whole lot” [https://youtube.com/shorts/j4zNjdz2uxY]. The compact magnetically-attached AI tracker is easily controlled by simple hand gestures, and makes professional-level video quick and easy to shoot – even for solo creators.

Other ZHIYUN accessories seen at NAB 2025 included:

Lights: Molus G300 and G200, Molus B series, Molus X100

Gimbals: Crane 4 and Weebill 3S

NAB Event details

Venue: Las Vegas Convention Center

Location: Las Vegas, Nevada, US

Date: April 6th to April 9th, 2025

www.nabshow.com

ZHIYUN Official Store Link: geni.us/ZHIYUN-Store-PR

Amazon Store: geni.us/AMZ-Store-PR-Sales

About ZHIYUN

ZHIYUN Tech is a pioneer and a world-leader in gimbals and stabilizers for everyone from professional filmmakers to amateur video creators. ZHIYUN believes in “MAKE IT REAL”: a commitment to arduous research and development to create breakthroughs in technological and industrial innovations. ZHIYUN’s standout products and features deliver everyday convenience, better experiences, and unlock new opportunities to make the imagination a reality. Learn more about ZHIYUN Tech at www.ZHIYUN-tech.com or check them out on Facebook: @ZHIYUNGlobal or follow them on Instagram: @ZHIYUN_Tech

Media Contact
Company Name: Guilin Zhishen Information Technology Co., Ltd.
Contact Person: Mei Chang
Email: Send Email
Phone: +86 400 900 6868
City: Shenzhen
Country: China
Website: https://www.zhiyun-tech.com/en

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ZHIYUN Shines Brighter at NAB 2025 With Latest Product Updates

BrightFunded Expands Trading Capabilities with Launch of Advanced cTrader Platform

BrightFunded, a leading global proprietary trading firm, today announced the launch of the powerful cTrader platform, significantly expanding trading capabilities for its global community of funded traders. This strategic addition provides BrightFunded traders with access to an advanced multi-asset trading environment known for its superior execution speed and sophisticated analytical tools.

The cTrader platform, developed by Spotware Systems, is now fully integrated into BrightFunded’s ecosystem, offering traders a comprehensive suite of advanced charting tools, rapid order execution capabilities, and an intuitive interface that serves both novice and experienced market participants.

“Today marks a pivotal moment in BrightFunded’s journey to deliver the best trading experience in the prop firm industry,” said Jelle Dijkstra, CEO of BrightFunded. “By incorporating cTrader into our platform offerings, we’re delivering on our commitment to provide our traders with a best-in-class experience, empowering them to elevate their trading performance and achieve consistent results in today’s dynamic markets.”

Enhanced Trading Experience

The addition of cTrader brings several key advantages to BrightFunded traders:

Top-Notch Stability: Engineered for reliability, ensuring uninterrupted access and smooth performance even during periods of high market volatility

Advanced Charting and Analysis: Sophisticated technical analysis tools with customizable indicators and drawing tools

Superior Execution Speed: Optimized order routing and execution technology designed to minimize delays

User-Friendly Interface: Intuitive design that accommodates traders of all experience levels

“Our traders’ success is at the core of everything we do at BrightFunded,” said Benjamin Galindo, Head of Operations. “The introduction of cTrader reflects our ongoing commitment to equipping our community with the most powerful and user-friendly tools available in the market. We believe this addition will significantly enhance our traders’ ability to analyze markets, execute strategies with precision, and ultimately achieve their financial goals.”

Availability

The cTrader platform is available to all BrightFunded traders starting today, April 9, 2025. Traders can access the platform through their existing BrightFunded accounts via the company’s website at www.brightfunded.com.

To celebrate, BrightFunded is launching a 36-Hour Flash Promo: Get 30% OFF with code ‘CTRADER30’ at checkout!

About BrightFunded

BrightFunded is a premier global proprietary trading firm that provides capital to skilled traders worldwide. Through its innovative funding programs, BrightFunded enables traders to access substantial virtual trading capital without risking their own funds, while offering the potential to earn significant profit splits. With a commitment to transparency, cutting-edge technology, and trader success, BrightFunded continues to set the standard in the proprietary trading industry.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: BrightFunded
Contact Person: Matt Wilson
Email: Send Email
City: Dubai
Country: United Arab Emirates
Website: brightfunded.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BrightFunded Expands Trading Capabilities with Launch of Advanced cTrader Platform

New York Underage DWI Attorney Rachel Kugel Discusses Legal Implications for Young Drivers

New York underage DWI attorney Rachel Kugel (https://thekugellawfirm.com/new-york-underage-dwi-attorney/) of The Kugel Law Firm provides crucial insight into the serious consequences young drivers face when charged with underage drinking and driving. New York law takes a strict stance on underage DWI offenses, imposing significant penalties that can have long-term effects on a person’s future. Whether a young driver is charged under the Zero Tolerance Law or faces more severe criminal charges, the consequences can include fines, license suspensions, and even the possibility of a permanent criminal record.

Rachel Kugel emphasizes the importance of understanding New York’s Zero Tolerance Law, which applies to drivers under 21 who are caught operating a vehicle with a Blood Alcohol Content (BAC) between 0.02% and 0.07%. While a BAC at this level may not result in traditional DWI charges, the penalties can still be severe. “Even a minimal amount of alcohol in an underage driver’s system can lead to legal trouble,” said the New York underage DWI attorney. “Young drivers and their families need to be aware of the consequences and take action immediately if they are facing charges.”

New York’s approach to underage DWI extends beyond the Zero Tolerance Law. Underage drivers who register a BAC of 0.08% or higher can be charged with standard Driving While Intoxicated (DWI), which carries the same legal penalties as it would for an adult. Additionally, if an underage driver’s BAC reaches 0.18% or higher, they may face Aggravated DWI charges, leading to even harsher penalties. The New York underage DWI attorney explains that these charges are taken seriously by the courts and can lead to lasting consequences that extend beyond the legal system.

A conviction for underage DWI in New York can lead to a variety of legal penalties. For those charged under the Zero Tolerance Law, consequences include a six-month license suspension, fines, and additional fees. A second offense can result in a one-year revocation or loss of driving privileges until the offender turns 21. However, for those charged with a criminal DWI or DWAI (Driving While Ability Impaired), penalties become even more severe, including higher fines, potential jail time, and longer license suspensions.

Rachel Kugel stresses that the impact of an underage DWI extends beyond legal penalties. A conviction can affect college admissions, military enlistment, and job opportunities. Many universities and employers conduct background checks, and having a DWI on record can make it harder for young adults to pursue their desired career paths. “This isn’t just about the legal consequences,” Kugel explains. “A DWI conviction can change the trajectory of a young person’s future, making it harder to get into college, secure scholarships, or even find employment.”

Additionally, underage drivers may face related charges, such as possession of alcohol as a minor or using a fake ID to purchase alcohol. These additional charges can further complicate their legal situation and lead to more severe penalties.

For young drivers facing underage DWI charges, having the right legal representation can make all the difference. Rachel Kugel and the team at The Kugel Law Firm analyze each case carefully to identify potential defense strategies. Some common defenses include challenging the legality of the traffic stop, questioning the accuracy of breathalyzer results, and examining whether law enforcement followed proper procedures.

“A strong defense can mean the difference between a conviction and a dismissal or reduced charges,” says Kugel. “We explore all possible avenues to challenge the evidence and protect our clients’ futures.”

For some underage drivers, alternative sentencing options may be available. New York offers diversion programs that focus on education and rehabilitation rather than punishment. Participation in these programs can help offenders avoid a permanent criminal record, reduce penalties, and provide them with resources to make better decisions in the future. Courts typically consider factors such as the driver’s BAC level, prior criminal history, and willingness to participate in rehabilitation programs when determining eligibility.

A single mistake should not define a young person’s future. Rachel Kugel and The Kugel Law Firm work diligently to minimize the impact of underage DWI charges on their clients’ lives. Whether through negotiating reduced charges, seeking alternative sentencing, or building a strong defense, their goal is to help clients move forward without lasting damage to their records and reputations.

For those facing underage DWI charges in New York, seeking legal assistance immediately is critical. Kugel urges families to take action quickly to pursue the best possible outcome. “The sooner you get legal representation, the better the chances of reducing or avoiding the most severe penalties,” Kugel advises.

About The Kugel Law Firm:

The Kugel Law Firm is dedicated to defending individuals facing DWI and DUI charges in New York. Led by attorney Rachel Kugel, the firm can provide aggressive legal representation aimed at minimizing penalties and protecting clients’ futures. With extensive knowledge of New York’s DWI laws, The Kugel Law Firm works tirelessly to build strong defenses and achieve the best possible outcomes for their clients.

Embeds:

Youtube Video: https://www.youtube.com/watch?v=_jK9Owqow7w

GMB: https://www.google.com/maps?cid=17189431107850367088

Email and website

Email: admin@thekugellawfirm.com

Website: https://thekugellawfirm.com/new-york-dwi-lawyer/

Media Contact
Company Name: The Kugel Law Firm
Contact Person: Rachel Kugel
Email: Send Email
Phone: (212) 372-7218
Address:111 E 125th St 2nd Fl
City: New York
State: New York 10035
Country: United States
Website: https://thekugellawfirm.com/new-york-dwi-lawyer/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New York Underage DWI Attorney Rachel Kugel Discusses Legal Implications for Young Drivers

DataMax System Solutions Welcomes Pat Gaynor as Head of Sales, Services Division

DataMax System Solutions announces Pat Gaynor as Head of Sales for its Services Division. With 27+ years of experience, Gaynor will lead national strategy across IT, CCTV, and maintenance services, supporting DataMax’s mission to drive cost savings, efficiency, and sustainable infrastructure for enterprise clients.

DataMax System Solutions is proud to announce the appointment of Pat Gaynor as the new Head of Sales for the Services Division, in Chicago, as the company continues to accelerate its services growth in the retail and hospitality industry.

With more than 27 years of experience in the industry, Pat is widely respected for his ability to drive revenue growth, build high-performing teams, and deliver service solutions that align with real-world operational needs. He joins DataMax following his leadership roles at CrossCom National and Telaid Industries, where he was instrumental in building high level strategic sales teams, with a focus on customer satisfaction in large enterprise clients.

“Pat brings a unique blend of strategic thinking, customer-first mentality, and deep industry insight,” said Elliott Wallace, Owner and CEO of DataMax System Solutions. “He understands the service ecosystem from every angle, and he knows how to build meaningful, lasting value for enterprise clients. We’re excited to see where he leads this next chapter.”

In his new role, Pat will lead the national sales strategy for DataMax’s fast-growing services division, which includes on premise field technician installations, projects, and support, Depot, and Batch Repair Maintenance programs, Hardware Lifecycle Management, IT Asset Disposition, and sustainable Recycling solutions. His vision aligns perfectly with DataMax’s mission to help businesses reduce costs, drive value of their existing infrastructure, and evolve smarter.

“This role was the right move at the right time,” said Gaynor. “The services team at DataMax is incredibly agile and customer focused. We have the ability to tailor solutions quickly and scale them across industries that need dependable, cost-effective IT, CCTV, and security hardware and services to stay operational and competitive.”

Pat’s appointment comes at a pivotal moment, as companies across retail and hospitality face tightening budgets, global sourcing disruptions, and rising demands for sustainability. DataMax continues to stand out by delivering nimble, cost-intelligent service models that meet these challenges head-on.

Media Contact
Company Name: DataMax System Solutions
Contact Person: Tara Kumar
Email: Send Email
Phone: 9545606739
Address:6251 Park of Commerce Boulevard
City: Boca Raton
State: Florida
Country: United States
Website: https://datamaxsys.com/